Download PDF
Am J Perinatol 2016; 33(12): 1191-1197
DOI: 10.1055/s-0036-1586119
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth

Kent D. Heyborne
1   Department of Obstetrics and Gynecology, Denver Health, Denver, Colorado
2   Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, Colorado
,
Amanda A. Allshouse
3   Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado
› Author Affiliations
Further Information

Publication History

09 June 2016

13 June 2016

Publication Date:
27 July 2016 (online)

    Permissions and Reprints

Abstract

Objective The objective of this study was to determine if maternal smoking modifies the effectiveness of 17 α-hydroxyprogesterone caproate (17OHP-C).

Study Design Secondary analysis of the Maternal-Fetal Medicine Units Network trial of 17OHP-C. The prevalence of preterm birth (PTB) by smoking status and treatment group was compared by chi-squared analysis and analysis of variance was used to compare gestational age (GA) at birth. Multivariable modeling was used to estimate the effect of smoking on 17OHP-C treatment.

Results In this study, 459 women were included. Maternal smoking significantly modified the effectiveness of 17OHP-C treatment. In smokers, 17OHP-C significantly reduced the prevalence of multiple outcomes (PTB < 37 and < 35 weeks, spontaneous PTB < 37 and < 35 weeks), while in nonsmokers, only PTB < 37 weeks was reduced. Delivery GA was later in 17OHP-C versus placebo treated smokers (36.4 vs. 34.3 weeks, p = 0.041) but not nonsmokers (36.3 vs. 35.5 weeks, p = nonsignificant). In multivariable modeling, 17OHP-C was more effective in smokers than nonsmokers as measured by multiple outcomes (PTB < 37 weeks [p = 0.041] and < 35 weeks [p = 0.036] and spontaneous PTB < 37 weeks [p = 0.029]).

Conclusion In this cohort of women with a prior PTB, maternal smoking status significantly modified the effectiveness of 17OHP-C treatment.

Keywords

17 α-hydroxyprogesterone caproate - 17OHP-C - smoking - preterm birth - progesterone - tobacco

Note

This study was presented at the Society for Maternal-Fetal Medicine's 36th Annual Meeting during Poster Session II on February 4, 2016, Control ID: 399.


 

  • References

  • 1 Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120 (4) 964-973
    CrossrefPubMedGoogle Scholar
  • 2 Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206 (5) 376-386
    CrossrefPubMedGoogle Scholar
  • 3 Meis PJ, Klebanoff M, Thom E , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348 (24) 2379-2385
    CrossrefPubMedGoogle Scholar
  • 4 Delpisheh A, Kelly Y, Rizwan S, Attia E, Drammond S, Brabin BJ. Population attributable risk for adverse pregnancy outcomes related to smoking in adolescents and adults. Public Health 2007; 121 (11) 861-868
    CrossrefPubMedGoogle Scholar
  • 5 Shiono PH, Klebanoff MA, Rhoads GG. Smoking and drinking during pregnancy. Their effects on preterm birth. JAMA 1986; 255 (1) 82-84
    CrossrefPubMedGoogle Scholar
  • 6 Tong VT, Dietz PM, Morrow B , et al; Centers for Disease Control and Prevention (CDC). Trends in smoking before, during, and after pregnancy—Pregnancy Risk Assessment Monitoring System, United States, 40 sites, 2000-2010. MMWR Surveill Summ 2013; 62 (6) 1-19
    PubMedGoogle Scholar
  • 7 Petrini JR, Callaghan WM, Klebanoff M , et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005; 105 (2) 267-272
    CrossrefPubMedGoogle Scholar
  • 8 Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371 (9606) 75-84
    CrossrefPubMedGoogle Scholar
  • 9 Manuck TA, Watkins WS, Moore B , et al. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. Am J Obstet Gynecol 2014; 210 (4) 321.e1-321.e21
    CrossrefPubMedGoogle Scholar
  • 10 Manuck TA, Esplin MS, Biggio J , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR). Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. Am J Obstet Gynecol 2016; 214 (3) 376.e1-376.e8
    CrossrefPubMedGoogle Scholar
  • 11 Meis PJ, Klebanoff M, Dombrowski MP , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstet Gynecol 2005; 106 (3) 557-561
    CrossrefPubMedGoogle Scholar
  • 12 Coleman S, Wallace L, Alexander J, Istwan N. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy. J Matern Fetal Neonatal Med 2012; 25 (7) 1034-1038
    CrossrefPubMedGoogle Scholar
  • 13 Gonzalez-Quintero VH, Cordova YC, Istwan NB , et al. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery. Am J Obstet Gynecol 2011; 205 (3) 275.e1-275.e5
    Google Scholar
  • 14 Caritis SN, Venkataramanan R, Thom E , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol 2014; 210 (2) 128.e1-128.e6
    CrossrefPubMedGoogle Scholar
  • 15 Heyborne KD, Allshouse AA, Carey JC. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?. Am J Obstet Gynecol 2015; 213 (6) 844.e1-844.e6
    CrossrefPubMedGoogle Scholar
  • 16 Toriola AT, Vääräsmäki M, Lehtinen M , et al. Determinants of maternal sex steroids during the first half of pregnancy. Obstet Gynecol 2011; 118 (5) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 17 Kiefer DG, Peltier MR, Keeler SM , et al. Efficacy of midtrimester short cervix interventions is conditional on intraamniotic inflammation. Am J Obstet Gynecol 2016; 214 (2) 276.e1-276.e6
    CrossrefPubMedGoogle Scholar
  • 18 Larsen B, Hwang J. Progesterone interactions with the cervix: translational implications for term and preterm birth. Infect Dis Obstet Gynecol 2011; 2011: 353297
    PubMedGoogle Scholar
  • 19 Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43 (10) 1731-1737
    CrossrefPubMedGoogle Scholar
  • 20 Cnattingius S, Granath F, Petersson G, Harlow BL. The influence of gestational age and smoking habits on the risk of subsequent preterm deliveries. N Engl J Med 1999; 341 (13) 943-948
    CrossrefPubMedGoogle Scholar
  • 21 Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014; 34 (3) 509-515
    CrossrefPubMedGoogle Scholar
  • 22 Connor Gorber S, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res 2009; 11 (1) 12-24
    CrossrefPubMedGoogle Scholar
  • 23 Klebanoff MA. 17 Alpha-hydroxyprogesterone caproate for preterm prevention: issues in subgroup analysis. Am J Obstet Gynecol 2016; 214 (3) 306-307
    CrossrefPubMedGoogle Scholar